Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Cytoki Pharma ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   26.1% 18.9% 8.0% 11.2% 9.2% 8.6% 7.6% 7.6%   Credit score (0-100)   3 7 29 21 26 29 32 32   Credit rating   B B BB BB BB BB BB BB   Credit limit (kDKK)   -0.0 -0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -2,124 -6,040 -31,975 -98,764 -61,548 -39,133 0.0 0.0   EBITDA   -2,858 -7,488 -36,962 -106,843 -70,094 -46,310 0.0 0.0   EBIT   -2,858 -7,488 -36,962 -106,843 -70,094 -46,310 0.0 0.0   Pre-tax profit (PTP)   -3,058.9 -8,279.5 -35,549.0 -103,893.6 -70,019.5 -44,761.7 0.0 0.0   Net earnings   -3,058.9 -6,793.4 -29,753.3 -98,393.6 -64,519.5 -39,261.7 0.0 0.0   Pre-tax profit without non-rec. items   -3,059 -8,280 -35,549 -103,894 -70,019 -44,762 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   -3,014 -9,808 106,806 51,217 66,697 57,274 56,916 56,916   Interest-bearing liabilities   8,396 15,842 0.0 1.4 1.8 1.8 0.0 0.0   Balance sheet total (assets)   5,624 7,048 116,214 68,865 73,927 62,886 56,916 56,916   Net Debt   2,886 11,127 -74,118 -54,919 -65,640 -55,636 -56,916 -56,916     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -2,124 -6,040 -31,975 -98,764 -61,548 -39,133 0.0 0.0   Gross profit growth   0.0% -184.4% -429.4% -208.9% 37.7% 36.4% 0.0% 0.0%   Employees   1 1 3 4 5 4 0 0   Employee growth %   0.0% 0.0% 200.0% 33.3% 25.0% -20.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   5,624 7,048 116,214 68,865 73,927 62,886 56,916 56,916   Balance sheet change%   0.0% 25.3% 1,548.9% -40.7% 7.3% -14.9% -9.5% 0.0%   Added value   -2,857.7 -7,488.1 -36,962.2 -106,843.0 -70,094.0 -46,310.4 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 -2.0 -3.0 -4.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   134.5% 124.0% 115.6% 108.2% 113.9% 118.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -33.0% -58.7% -53.0% -110.6% -97.4% -65.2% 0.0% 0.0%   ROI %   -33.9% -61.7% -57.5% -129.6% -117.9% -72.0% 0.0% 0.0%   ROE %   -54.4% -107.2% -52.3% -124.5% -109.4% -63.3% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   -34.9% -58.2% 91.9% 74.4% 90.2% 91.1% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -101.0% -148.6% 200.5% 51.4% 93.6% 120.1% 0.0% 0.0%   Gearing %   -278.5% -161.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   5.0% 6.6% 3.7% 226,058.2% 32,892.1% 8,438.1% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   23.1 0.4 12.3 3.9 10.2 11.2 0.0 0.0   Current Ratio   23.1 0.4 12.3 3.9 10.2 11.2 0.0 0.0   Cash and cash equivalent   5,509.8 4,715.7 74,117.5 54,920.3 65,641.4 55,637.8 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   5,363.5 -9,825.9 106,706.1 51,135.8 66,557.1 57,126.6 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -2,858 -7,488 -12,321 -26,711 -14,019 -11,578 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -2,858 -7,488 -12,321 -26,711 -14,019 -11,578 0 0   EBIT / employee   -2,858 -7,488 -12,321 -26,711 -14,019 -11,578 0 0   Net earnings / employee   -3,059 -6,793 -9,918 -24,598 -12,904 -9,815 0 0